Wolters Kluwer Logo Wolters Kluwer Logo
Open search
Search suggestion
Open suggestion box
Search suggestion
log in button See related products
arrow down
Kluwer Patent Blog
Search filters
Clear all
GENERAL PREFERENCES
Search only titles
Jurisdiction
Category
Tags
Contributor
Affiliate
Date
From
To
End date must be later than the start date.

Search Results for:

13 results available

search-result-placeholder.jpg
Mami Hino  (Abe, Ikubo & Katayama) , Naho Ebata  (Abe, Ikubo & Katayama)
Japan IP High Court Clarified Scope of Patent Term Extension and Awarded Highest Ever Damages in Landmark Nalfurafine Case
June 05, 2025

On May 27, 2025, the Intellectual Property High Court of Japan ruled in favor of Toray Industries, Inc. in a landmark patent infringement lawsuit (Case No. 2021 (Ne) 10037) concerning the extended…

  • Read more
search-result-placeholder.jpg
Mami Hino  (Abe, Ikubo & Katayama)
Japan’s first case regarding compulsory license based on public interest is finally settled
July 05, 2024

On May 30, 2024, the JPO announced that the request for a decision of granting a compulsory non-exclusive license based on public interest under Article 93 of the Patent Act, which was filed by…

  • Read more
search-result-placeholder.jpg
Mami Hino  (Abe, Ikubo & Katayama) , Naho Ebata  (Abe, Ikubo & Katayama) , Shoichiro Kajinami  (Abe, Ikubo & Katayama)
Japan: Sawai’s Generic Drug is approved by the MHLW amid patent litigation with Bristol-Myers Squibb, but the Court orders preliminary injunction against Sawai soon after
January 09, 2024

On November 28, 2023, the Tokyo District Court issued a preliminary injunction order against Sawai Pharmaceutical Co., Ltd. (“Sawai”) to suspend the manufacture and sale of Sawai’s pharmaceutical…

  • Read more
search-result-placeholder.jpg
Mami Hino  (Abe, Ikubo & Katayama) , Naho Ebata  (Abe, Ikubo & Katayama)
Amgen v. Sanofi and Regeneron: Japan IP High Court overrules its own decision on validity of Amgen patent
May 15, 2023

On January 26, 2023, Regeneron Pharmaceuticals, Inc., who sought to invalidate Amgen Inc.’s Japanese patent (JP5705288) covering an isolated monoclonal antibody used as cholesterol medication, won an…

  • Read more
search-result-placeholder.jpg
Mami Hino  (Abe, Ikubo & Katayama) , Naho Ebata  (Abe, Ikubo & Katayama) , Shoichiro Kajinami  (Abe, Ikubo & Katayama)
Japan IP High Court’s first-ever decision allowing patent enforcement against infringing acts partially committed outside of Japan
December 12, 2022

On July 20, 2022, the Japan Intellectual Property High Court (“IP High Court”) rendered the first-ever decision allowing enforcement of Japanese patent rights against infringing acts partially…

  • Read more
search-result-placeholder.jpg
Naho Ebata  (Abe, Ikubo & Katayama) , Mami Hino  (Abe, Ikubo & Katayama)
Japan: The government of Japan announces the Intellectual Property Strategic Program 2022. Important changes on the horizon for patents owned jointly by universities and commercial companies
August 23, 2022

On June 3, 2022, the Japanese government announced its Intellectual Property Strategic Program 2022. The Intellectual Property Strategic Program sets out the government’s policies and future actions…

  • Read more
search-result-placeholder.jpg
Naho Ebata  (Abe, Ikubo & Katayama) , Mami Hino  (Abe, Ikubo & Katayama)
JPO publishes the Status Report 2022
June 10, 2022

Every year the Japan Patent Office (JPO) publishes a status report in spring, and this year’s report (the “Status Report 2022”) was published on March 30, 2022. The Status Report 2022 contains…

  • Read more
search-result-placeholder.jpg
Naho Ebata  (Abe, Ikubo & Katayama) , Mami Hino  (Abe, Ikubo & Katayama)
Japan: Problem of Japan’s patent linkage system comes to the surface by a set of IP High Court decisions
May 10, 2022

The “patent linkage system” is in general a system wherein market approval of generic drugs is linked with the status of the originator drug’s patents, for the purpose of early resolution of patent…

  • Read more
search-result-placeholder.jpg
Mami Hino  (Abe, Ikubo & Katayama) , Naho Ebata  (Abe, Ikubo & Katayama)
Japan: PD-1/PD-L1 related patents: What are the co-inventorship requirements for an invention in the medicine field
April 07, 2022

The hurdle for being a co-inventor in a medicine field in Japan might be a little higher than what is expected from precedents. The IP High Court affirmed, in its judgement of 17th March 2021 (2020 (…

  • Read more
search-result-placeholder.jpg
Naho Ebata  (Abe, Ikubo & Katayama) , Mami Hino  (Abe, Ikubo & Katayama)
Japan: MSD v Wyeth - The IP High Court upholds the validity of patent claims, finding inventive step in the functional limitation therein
October 28, 2021

In Japanese patent litigation, calling expert witnesses is very rare and the parties usually try to prove common technical knowledge (CGK) by submitting documentary evidence, such as publications…

  • Read more
1 - 10 of 13 results
  • 1
  • 2
  • About Kluwer Patent Blog
  • Contact Us
  • Wolters Kluwer: IP Law
    Wolters Kluwer: IP Law
  • Wolters Kluwer on X
    Wolters Kluwer: X
  • KLI YouTube
    YouTube
  • Editorial Policy & Guidelines
  • Privacy Policy and Use of Cookies
  • User Agreement and Disclaimer

© 2025 Wolters Kluwer N.V. and/or its subsidiaries. All rights reserved.